BDBM235766 US9359371, Avanafil

SMILES COc1ccc(CN=c2[nH]c(ncc2C(O)=NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl

InChI Key InChIKey=WEAJZXNPAWBCOA-UHFFFAOYSA-N

Data  24 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 24 hits for monomerid = 235766   

TargetcGMP-specific 3',5'-cyclic phosphodiesterase [537-875](Human)
Xuanzhu Pharma

US Patent
LigandPNGBDBM235766(US9359371, Avanafil)
Affinity DataIC50: 6.99nMpH: 7.5Assay Description:To a 96-well plate, 20 μL, of 10 μM FL-cGMP as the substrate was added; then 1 μL, of solution of the compound in DMSO or DMSO solutio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase [537-875](Human)
Xuanzhu Pharma

US Patent
LigandPNGBDBM235766(US9359371, Avanafil)
Affinity DataIC50: 8.56nMpH: 7.5Assay Description:To a 96-well plate, 20 μL, of 10 μM FL-cGMP as the substrate was added; then 1 μL, of solution of the compound in DMSO or DMSO solutio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase [537-875](Human)
Xuanzhu Pharma

US Patent
LigandPNGBDBM235766(US9359371, Avanafil)
Affinity DataIC50: 9.29nMpH: 7.5Assay Description:To a 96-well plate, 20 μL, of 10 μM FL-cGMP as the substrate was added; then 1 μL, of solution of the compound in DMSO or DMSO solutio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase [537-875](Human)
Xuanzhu Pharma

US Patent
LigandPNGBDBM235766(US9359371, Avanafil)
Affinity DataIC50: 10.8nMpH: 7.5Assay Description:To a 96-well plate, 20 μL, of 10 μM FL-cGMP as the substrate was added; then 1 μL, of solution of the compound in DMSO or DMSO solutio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase [537-875](Human)
Xuanzhu Pharma

US Patent
LigandPNGBDBM235766(US9359371, Avanafil)
Affinity DataIC50: 10.8nMpH: 7.5Assay Description:To a 96-well plate, 20 μL, of 10 μM FL-cGMP as the substrate was added; then 1 μL, of solution of the compound in DMSO or DMSO solutio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase [537-875](Human)
Xuanzhu Pharma

US Patent
LigandPNGBDBM235766(US9359371, Avanafil)
Affinity DataIC50: 10.8nMpH: 7.5Assay Description:To a 96-well plate, 20 μL, of 10 μM FL-cGMP as the substrate was added; then 1 μL, of solution of the compound in DMSO or DMSO solutio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase [537-875](Human)
Xuanzhu Pharma

US Patent
LigandPNGBDBM235766(US9359371, Avanafil)
Affinity DataIC50: 10.8nMpH: 7.5Assay Description:To a 96-well plate, 20 μL, of 10 μM FL-cGMP as the substrate was added; then 1 μL, of solution of the compound in DMSO or DMSO solutio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase [537-875](Human)
Xuanzhu Pharma

US Patent
LigandPNGBDBM235766(US9359371, Avanafil)
Affinity DataIC50: 10.8nMpH: 7.5Assay Description:To a 96-well plate, 20 μL, of 10 μM FL-cGMP as the substrate was added; then 1 μL, of solution of the compound in DMSO or DMSO solutio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase [537-875](Human)
Xuanzhu Pharma

US Patent
LigandPNGBDBM235766(US9359371, Avanafil)
Affinity DataIC50: 12.3nMpH: 7.5Assay Description:To a 96-well plate, 20 μL, of 10 μM FL-cGMP as the substrate was added; then 1 μL, of solution of the compound in DMSO or DMSO solutio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase [537-875](Human)
Xuanzhu Pharma

US Patent
LigandPNGBDBM235766(US9359371, Avanafil)
Affinity DataIC50: 12.5nMpH: 7.5Assay Description:To a 96-well plate, 20 μL, of 10 μM FL-cGMP as the substrate was added; then 1 μL, of solution of the compound in DMSO or DMSO solutio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase [537-875](Human)
Xuanzhu Pharma

US Patent
LigandPNGBDBM235766(US9359371, Avanafil)
Affinity DataIC50: 17.3nMpH: 7.5Assay Description:To a 96-well plate, 20 μL, of 10 μM FL-cGMP as the substrate was added; then 1 μL, of solution of the compound in DMSO or DMSO solutio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase [537-875](Human)
Xuanzhu Pharma

US Patent
LigandPNGBDBM235766(US9359371, Avanafil)
Affinity DataIC50: 17.3nMpH: 7.5Assay Description:To a 96-well plate, 20 μL, of 10 μM FL-cGMP as the substrate was added; then 1 μL, of solution of the compound in DMSO or DMSO solutio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase [537-875](Human)
Xuanzhu Pharma

US Patent
LigandPNGBDBM235766(US9359371, Avanafil)
Affinity DataIC50: 17.3nMpH: 7.5Assay Description:To a 96-well plate, 20 μL, of 10 μM FL-cGMP as the substrate was added; then 1 μL, of solution of the compound in DMSO or DMSO solutio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase [537-875](Human)
Xuanzhu Pharma

US Patent
LigandPNGBDBM235766(US9359371, Avanafil)
Affinity DataIC50: 17.3nMpH: 7.5Assay Description:To a 96-well plate, 20 μL, of 10 μM FL-cGMP as the substrate was added; then 1 μL, of solution of the compound in DMSO or DMSO solutio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase [537-875](Human)
Xuanzhu Pharma

US Patent
LigandPNGBDBM235766(US9359371, Avanafil)
Affinity DataIC50: 17.3nMpH: 7.5Assay Description:To a 96-well plate, 20 μL, of 10 μM FL-cGMP as the substrate was added; then 1 μL, of solution of the compound in DMSO or DMSO solutio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase [537-875](Human)
Xuanzhu Pharma

US Patent
LigandPNGBDBM235766(US9359371, Avanafil)
Affinity DataIC50: 17.3nMpH: 7.5Assay Description:To a 96-well plate, 20 μL, of 10 μM FL-cGMP as the substrate was added; then 1 μL, of solution of the compound in DMSO or DMSO solutio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase [537-875](Human)
Xuanzhu Pharma

US Patent
LigandPNGBDBM235766(US9359371, Avanafil)
Affinity DataIC50: 17.3nMpH: 7.5Assay Description:To a 96-well plate, 20 μL, of 10 μM FL-cGMP as the substrate was added; then 1 μL, of solution of the compound in DMSO or DMSO solutio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase [537-875](Human)
Xuanzhu Pharma

US Patent
LigandPNGBDBM235766(US9359371, Avanafil)
Affinity DataIC50: 20.9nMpH: 7.5Assay Description:To a 96-well plate, 20 μL, of 10 μM FL-cGMP as the substrate was added; then 1 μL, of solution of the compound in DMSO or DMSO solutio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase [537-875](Human)
Xuanzhu Pharma

US Patent
LigandPNGBDBM235766(US9359371, Avanafil)
Affinity DataIC50: 20.9nMpH: 7.5Assay Description:To a 96-well plate, 20 μL, of 10 μM FL-cGMP as the substrate was added; then 1 μL, of solution of the compound in DMSO or DMSO solutio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase [537-875](Human)
Xuanzhu Pharma

US Patent
LigandPNGBDBM235766(US9359371, Avanafil)
Affinity DataIC50: 20.9nMpH: 7.5Assay Description:To a 96-well plate, 20 μL, of 10 μM FL-cGMP as the substrate was added; then 1 μL, of solution of the compound in DMSO or DMSO solutio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase [537-875](Human)
Xuanzhu Pharma

US Patent
LigandPNGBDBM235766(US9359371, Avanafil)
Affinity DataIC50: 20.9nMpH: 7.5Assay Description:To a 96-well plate, 20 μL, of 10 μM FL-cGMP as the substrate was added; then 1 μL, of solution of the compound in DMSO or DMSO solutio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase [537-875](Human)
Xuanzhu Pharma

US Patent
LigandPNGBDBM235766(US9359371, Avanafil)
Affinity DataIC50: 26.0nMpH: 7.5Assay Description:To a 96-well plate, 20 μL, of 10 μM FL-cGMP as the substrate was added; then 1 μL, of solution of the compound in DMSO or DMSO solutio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase [537-875](Human)
Xuanzhu Pharma

US Patent
LigandPNGBDBM235766(US9359371, Avanafil)
Affinity DataIC50: 26.0nMpH: 7.5Assay Description:To a 96-well plate, 20 μL, of 10 μM FL-cGMP as the substrate was added; then 1 μL, of solution of the compound in DMSO or DMSO solutio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase [537-875](Human)
Xuanzhu Pharma

US Patent
LigandPNGBDBM235766(US9359371, Avanafil)
Affinity DataIC50: 26.0nMpH: 7.5Assay Description:To a 96-well plate, 20 μL, of 10 μM FL-cGMP as the substrate was added; then 1 μL, of solution of the compound in DMSO or DMSO solutio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent